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 Systems approach to valuing biotech / cell therapy investment opportunities:
 Cost-effective process and facility design
 Batch v continuous (Lim et al, 2005 & 2006; Pollock et al, 2013a, 2013b; Farid et al, 2014)
 Chromatography optimisation (Stonier et al, 2012; Simaria et al, 2012; Allmendinger et al, 2014)
 SUT for allogeneic cell therapies (Simaria et al, 2014; Hassan et al, 2015)
 Capacity planning & Portfolio management
 Portfolio management & capacity sourcing (Rajapakse et al, 2006; George & Farid, 2008a,b)
 Multi-site long term production planning (Lakhdar et al, 2007; Siganporia et al, 2012)
 Facility fit
 Prediction of suboptimal facility fit upon tech transfer (Stonier et al, 2013; Yang et al, 2014)










































































Process economics: integrated conti bioprocesses
Key questions addressed:
 Fed-batch versus perfusion systems
(Pollock et al, 2013a)
 Impact of scale on COG/g?
 Imp ct of failures rat s on robustn ss?
 Continuous chromatography
(Pollock et al, 2013b)
 Clinical v commercial COG/g?
 Retrofit costs across devt phases?
 Integrated continuous processing
(Farid et al, 2014)
 Impact of development phase, company
size and portfolio size on COG/g of ICB?
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Process economics: integrated conti bioprocesses
 Fed-batch versus perfusion systems (Pollock et al, 2013a)
 Continuous chromatography (Pollock et al, 2013b)
 Integrated continuous processing (Farid et al, 2014)
Pollock, Ho & Farid, 2013, Biotech Bioeng, 110(1): 206–219
Fed-batch versus perfusion – commercial
• ATF Perfusion processes can offer up to
20% COG/g savings
• Cell density for ATF to compete with FB is
x3-5–fold higher
• FB – most robust process
• ATF – lowest COG even when accounting for
higher variability
• FB and ATF tied if operational and financial
benefits weighted equally
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Farid, Pollock & Ho, 2014, In Subramanian, G. (ed.), Ch 17, pp 433-455.Pollock, Bolton, Coffman, Ho, Bracewell, Farid, 2013, J Chrom A, 1284: 17-27
Process economics: integrated conti bioprocesses
 Fed-batch versus perfusion systems (Pollock et al, 2013a)
 Continuous chromatography (Pollock et al, 2013b)
 Integrated continuous processing (Farid et al, 2014)
Continuous chrom – clinical v commercial
• Continuous chrom offers more significant
savings for early phase manufacture
• ~30% COGdirect savings @ early clinical
v ~5% COGdirect savings @ commercial
Integrated conti processes - multiproduct
• ICB offers savings for smaller portfolio
sizes and early phase processes
• Hybrid processes can be more economical
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Facility Optimisation: Conti chrom & prepacked
Key questions addressed:
How do the feed characteristics and resin
properties impact the optimal number of
columns to have in a continuous
chromatography system?
Does the adoption of pre-packed
disposable columns change the feasibility of
continuous chromatography?
Allmendinger, Farid, in preparation
8
• Chromatographic parameters to optimize
• Column diameter






Facility Optimisation: Conti chrom & prepacked
Allmendinger, Farid, in preparation
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• Chromatographic parameters to optimize
• Column diameter
• Column bed height
• Loading-linear velocity
• #Columns
• Column type: Self-Packed (SP) Glass




Facility Optimisation: Conti chrom & prepacked





+ Flexibility and ready to use
+ Reduced risk of packing failures
+ Reduced validation efforts
- Limited in size (up to 60cm)
- Pre-packed column costs
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• Chromatographic parameters to optimize
• Column diameter
• Column bed height
• Loading-linear velocity
• #Columns
• Column type: SP Glass vs PP Dispo




Facility Optimisation: Conti chrom & prepacked
Allmendinger, Farid, in preparation
Continuous
+ Improved resin capacity utilization
+ Reduced buffer consumption
- Increased complexity
- High skid price
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• Chromatographic parameters to optimize
• Column diameter
• Column bed height
• Loading-linear velocity
• #Columns
• Column type: SP Glass vs PP Dispo
• Chromatography mode: Batch vs Continuous
• Optimization goal
Minimize Cost of Goods = Materials + Labour + Suite + Equipment Depreciation
Facility Optimisation: Conti chrom & prepacked























































Capacity planning: fed-batch v perfusion portfolios
Key questions addressed:
 Portfolio of labile perfusion products +
stable fed-batch products:
What is the trade-off between retrofitting
v. CMOs v. new build to cope with a
portfolio of fed-batch and labile perfusion
candidates?
 Portfolio of stable products with option
of perfusion or fed-batch processes:
How robust are fed-batch v. perfusion




• How best can we use existing capacity in multiple
facilities to meet commercial demands?
• Should CMOs or a future facility be considered?
• When and how much capital expenditure is required?
Approach:
• Mixed-integer linear programming
• Minimise total cost
Multiple products Multiple facilities
Batch and semi-continuous processes
Project Aims
Siganporia, Ghosh, Daskowski, Papageorgiou, & Farid, 2014, Biotechnol Progress. 30 (3), 594–606
Capacity planning: fed-batch v perfusion portfolios
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Perfusion scheduling challenges
Siganporia, Ghosh, Daskowski, Papageorgiou, & Farid, 2014, Biotechnol Progress. 30 (3), 594–606









Siganporia, Ghosh, Daskowski, Papageorgiou, & Farid, 2014, Biotechnol Progress. 30 (3), 594–606




















• Total costs = Production
Cost + Inventory Cost +
Investment for future
facility + Retrofitting cost






Question: Given projected commercial demands over 8 years of 4 products:
- should CMOs, a new build, or retrofitting an existing facility be considered?
- how best should production be allocated across facilities?
Siganporia, Ghosh, Daskowski, Papageorgiou, & Farid, 2014, Biotechnol Progress. 30 (3), 594–606
Capacity planning: fed-batch v perfusion portfolios
Case Study: portfolio of labile and stable products
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1 2 3 … 7 8
Perf1 Perfusion 150 days 24 20 20 20 … 28 30
Perf2 Perfusion 60 days 24 0 0 1 … 10 12
Perf3 Perfusion 28 days 24 0 0 0 … 0.44 0.45
FB1 Fed-batch 14 days 24 0 0 0 … 3030 3330
Facility Manufacturing Capability
Perf1 Perf2 Perf3 FB1





Perf1 - Perf3 FB1
6 x 200 L 2 x 3000 L
* Retrofitting is required
Siganporia, Ghosh, Daskowski, Papageorgiou, & Farid, 2014, Biotechnol Progress. 30 (3), 594–606
Capacity planning: fed-batch v perfusion portfolios



















• A combination of both a CMO and future build is necessary to meet market demand.
• Customer service level drops below 100% in the final year.
• Instead of retrofitting f1’s DSP suite, DSP production is carried out in the future build
Facility
Year









• Production of Perf3 and any excess demand of FB1 is outsourced to CMO.
• Products are kept within one facility if possible so as to minimise licence fees.
• Facility f1 is not used for the downstream production of products Perf1 and Perf2 to minimise retrofitting.
Perf1 Perf2 Perf3 FB1
Siganporia, Ghosh, Daskowski, Papageorgiou, & Farid, 2014, Biotechnol Progress. 30 (3), 594–606
Demand Variation
Case Study: portfolio of labile and stable products
Capacity planning: fed-batch v perfusion portfolios
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UCL Decisional Tools Summary
Therapeutic candidate in early phase development with:
• Early clinical data
- e.g. cell type, dose estimate, patient numbers
• Early process data
- e.g. yields
UCL Decisional Tools outputs can be used to help with decision-making:
 Compare the cost-effectiveness of alternative manufacturing processes / supply chains
 Identify the most cost-effective and GMP-ready process for
 current scale of operation
 future scales for late phase / commercial manufacture
 Predict and manage the risk of process changes as products proceed through
development pathway
 Identify most promising technologies and targets to reach for future R&D investment
 Optimise capacity planning across multi-site multiproduct facilities
Biotech / Cell therapy company
UCL Decisional Tools researchers
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